China Shandong International Asset Management Limited (“CSIAM”) was established in 2019 and was approved by the Securities and Futures Commission (SFC) to engage in Type 1 (Dealing in Securities), Type 4 (Advising on Securities) and Type 9 (Asset Aanagement) regulated activities.


As an investment and financing management platform of China Shandong Group Company Limited (“CSGL”) in Hong Kong, CSIAM provides securities trading and asset management service related to fixed income, equity, privatization, mergers and acquisitions investment and financing, cornerstone investment and Pre-IPO services to investors.


CSGL, the parent company of CSIAM, was established in Hong Kong in 1985, mainly engaging in the Shandong Province's economic and trade activities in Hong Kong. CSGL is also the predecessor of Hualu Holdings Company Limited (“Hualu Holdings”) which is a state-owned enterprise. It operates in Shandong Province, with 3 major industries including high-end chemical industry, biomedicine and ecological environmental protection as its core businesses. Hualu Holdings has actual control of Shandong Hualu Hengsheng Chemical Co Ltd (stock code: 600426), Shandong Xinhua Pharmaceutical Co Ltd (Stock code: H share 0719; A share 000756), Shandong Lukang Pharmaceutical Co Ltd (Stock code: 600789), and 5 non-listed companies including Shandong Academy of Environmental Sciences Company Limited and CSGL.